• Simcere Pharmaceutical Group, of Nanjing, China, entered a $495 million definitive merger agreement with Simcere Holding Ltd. and Simcere Acquisition Ltd., a deal that would take the company private. Read More
• Orexo AB, of Uppsala, Sweden, said it completed a dose-finding study of OX51, a sublingual formulation comprising alfentanil, in patients undergoing prostate biopsy, with the trial meeting its primary endpoint of analgesic efficacy. Read More
• Horizon Pharma Inc., of Deerfield, Ill., and its partner Skyepharma plc, of London, filed a patent infringement lawsuit against Watson Laboratories Inc., of Parsippany, N.J., in the U.S. District Court for the District of New Jersey. Read More
In recent years, culturing methods have enabled researchers to generate model tissues that are far more life-like than the single sheets of single cell types that were once the only game in town for cell culture research. Read More
R&D and “efficiency” aren’t terms that seem to naturally blend together when applied to the operations of the biopharmaceutical industry. One only has to point to the many billions of dollars that companies pour into research and development annually. Read More
Shares of Astex Pharmaceuticals Inc. surged 24 percent Wednesday on top-line results from the company’s Phase II trial of cancer candidate SGI-110 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Read More
Merck Serono SA spinout Obseva SA hit the ground running with a CHF32 million (US$34.7 million) Series A financing led by Sofinnova Partners and co-led by Sofinnova Ventures and Novo A/S. Read More
